A Phase 1b Study of ABBV-383 in People With Amyloid Light Chain Amyloidosis

Full Title

Purpose

The purpose of this study is to find the best dose of ABBV-383 to treat AL amyloidosis. The people in this study have AL amyloidosis that came back or does not get better with treatment.

ABBV-383 is a type of drug called a bispecific antibody. It binds to one protein on cancer cells and to another on immune cells called T cells. ABBV-383 may strengthen your immune system’s ability to fight cancer cells by activating your own cells to destroy your tumor. It is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

• Have AL amyloidosis that came back or is not getting better after treatment.
• Have recovered from the serious side effects of prior treatments before getting ABBV-383.
• Be able to walk and do routine activities for more than half the time you are awake.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Heather Landau’s office at 646-608-3740.